LGDN Stock Overview A biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Add noteLigand Pharmaceuticals Incorporated Competitors Price History & Performance
Summary of share price highs, lows and changes for Ligand Pharmaceuticals Historical stock prices Current Share Price US$109.00 52 Week High US$120.00 52 Week Low US$63.50 Beta 0.93 1 Month Change -1.80% 3 Month Change 19.78% 1 Year Change 70.31% 3 Year Change -21.67% 5 Year Change 15.34% Change since IPO 31.13%
Recent News & Updates
Ligand Pharmaceuticals Incorporated Reiterates Earnings Guidance for 2024 and Provides Earnings Guidance for 2025 Dec 11
Third quarter 2024 earnings released: US$0.39 loss per share (vs US$0.59 loss in 3Q 2023) Nov 08
Ligand Pharmaceuticals Incorporated Revises Earnings Guidance for the Year 2024 Nov 08
Ligand Pharmaceuticals Incorporated to Report Q3, 2024 Results on Nov 07, 2024 Oct 24
President & COO recently sold €1.8m worth of stock Aug 28
CEO & Director recently bought €223k worth of stock Aug 12 See more updates
Ligand Pharmaceuticals Incorporated Reiterates Earnings Guidance for 2024 and Provides Earnings Guidance for 2025 Dec 11
Third quarter 2024 earnings released: US$0.39 loss per share (vs US$0.59 loss in 3Q 2023) Nov 08
Ligand Pharmaceuticals Incorporated Revises Earnings Guidance for the Year 2024 Nov 08
Ligand Pharmaceuticals Incorporated to Report Q3, 2024 Results on Nov 07, 2024 Oct 24
President & COO recently sold €1.8m worth of stock Aug 28
CEO & Director recently bought €223k worth of stock Aug 12
Second quarter 2024 earnings released: US$2.88 loss per share (vs US$0.13 profit in 2Q 2023) Aug 07
Ligand Pharmaceuticals Incorporated Reaffirms Financial Guidance for the Full Year of 2024 Aug 07
Investor sentiment deteriorates as stock falls 15% Aug 05
Ligand Pharmaceuticals Incorporated to Report Q2, 2024 Results on Aug 06, 2024 Jul 24
Investor sentiment improves as stock rises 16% Jul 12
Ligand Pharmaceuticals Incorporated (NasdaqGM:LGND) entered into an agreement to acquire APEIRON Biologics AG for $128 million. Jul 09
Ligand Pharmaceuticals Incorporated Revises Earnings Guidance for the Year 2024 Jul 08
Ligand Collaborator Merck Receives FDA Approval for CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Adults Jun 18
President & COO recently sold €1.4m worth of stock May 16
New major risk - Earnings quality May 10
Ligand Pharmaceuticals Incorporated Reaffirms Earnings Guidance for the Year 2024 May 09
First quarter 2024 earnings released: EPS: US$4.86 (vs US$2.56 in 1Q 2023) May 08
Ligand Pharmaceuticals Incorporated, Annual General Meeting, Jun 14, 2024 Apr 27
Ligand Pharmaceuticals Incorporated to Report Q1, 2024 Results on May 07, 2024 Apr 24
Ligand Pharmaceuticals Incorporated Announces New Topiram Injection Data Presented At 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference Apr 09
New minor risk - Share price stability Apr 05
Investor sentiment deteriorates as stock falls 15% Mar 07
Ligand Pharmaceuticals Incorporated Re-Affirms Earnings Guidance for 2024 Feb 29
Full year 2023 earnings released: EPS: US$3.11 (vs US$0.31 loss in FY 2022) Feb 28
Ligand Pharmaceuticals Incorporated Announces Management Appointments Feb 16
Ligand Pharmaceuticals Incorporated to Report Q4, 2023 Results on Feb 27, 2024 Feb 14
U.S. Food and Drug Administration Approves ZELSUVMI as a First-in-Class Medication for the Treatment of Molluscum Contagiosum Jan 06
Ligand Pharmaceuticals Incorporated Provides Earnings Guidance for the Year 2024 Dec 13
Third quarter 2023 earnings released: US$0.74 loss per share (vs US$0.024 profit in 3Q 2022) Nov 10
Ligand Pharmaceuticals Incorporated Revises Earnings Guidance for the Year 2023 Nov 10
Ligand Pharmaceuticals Incorporated to Report Q3, 2023 Results on Nov 08, 2023 Oct 26
Ligand Pharmaceuticals Incorporated (NasdaqGM:LGND) completed the acquisition of Substantially All of the Assets of Novan, Inc. Sep 28
CEO & Director recently bought €223k worth of stock Sep 27
Ligand Pharmaceuticals Incorporated Appoints Martine Zimmermann to its Board of Directors Sep 27
Ligand Pharmaceuticals Incorporated Reaffirms Revenue Guidance for 2023 Aug 11
Second quarter 2023 earnings released: EPS: US$0.13 (vs US$0.053 loss in 2Q 2022) Aug 09
Ligand Pharmaceuticals Incorporated (NasdaqGM:LGND) announces an Equity Buyback for $50 million worth of its shares. Aug 09
Ligand's Collaborator Merck Announces V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Met Key Immunogenicity and Safety Endpoints in Two Phase 3 Trials Jul 28
Ligand Pharmaceuticals Incorporated to Report Q2, 2023 Results on Aug 08, 2023 Jul 26
Ligand Pharmaceuticals Incorporated (NasdaqGM:LGND) entered into a stalking horse asset purchase agreement to acquire Substantially All of the Assets of Novan, Inc. for $15 million. Jul 18
Independent Chairman recently sold €316k worth of stock May 22
First quarter 2023 earnings released: EPS: US$2.56 (vs US$0.91 loss in 1Q 2022) May 07
Ligand Pharmaceuticals Incorporated Raises Earnings Guidance for 2023 May 06
Full year 2022 earnings released: US$0.31 loss per share (vs US$3.44 profit in FY 2021) Feb 24
Ligand Pharmaceuticals Incorporated to Report Q4, 2022 Results on Feb 22, 2023 Feb 07 Ligand Pharmaceuticals Incorporated Announces CEO Changes
Insufficient new directors Nov 16
Chief Financial Officer recently sold €128k worth of stock Nov 11
Third quarter 2022 earnings released: EPS: US$0.024 (vs US$0.82 in 3Q 2021) Nov 09
Ligand Pharmaceuticals Incorporated Provides Revenue Guidance for the Year 2022 Nov 08
Insufficient new directors Nov 03 Ligand Pharmaceuticals Incorporated Appoints Octavio (Tavo) Espinoza as Chief Financial Officer
Ligand Pharmaceuticals Incorporated to Report Q3, 2022 Results on Nov 07, 2022 Oct 27
CEO & Executive Director recently sold €180k worth of stock Sep 17
Second quarter 2022 earnings released: US$0.053 loss per share (vs US$1.84 profit in 2Q 2021) Aug 10
Ligand Pharmaceuticals Incorporated Provides Revenue Guidance for the Full Year 2022 Aug 10
Ligand Pharmaceuticals Incorporated to Report Q2, 2022 Results on Aug 08, 2022 Jul 23
Ligand Pharmaceuticals Incorporated Appoints Jason Haas to its Board of Directors Jun 30
Investor sentiment improved over the past week Jun 25
President & COO recently bought €199k worth of stock May 14
First quarter 2022 earnings released: US$0.91 loss per share (vs US$1.10 profit in 1Q 2021) May 06
Ligand Pharmaceuticals Incorporated, Annual General Meeting, Jun 10, 2022 Apr 23
Ligand Pharmaceuticals Incorporated to Report Q1, 2022 Results on May 04, 2022 Apr 20
Investor sentiment deteriorated over the past week Feb 24
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Feb 19
Ligand Pharmaceuticals Incorporated Provides Revenue Guidance for the Year 2022 Feb 18
Ligand Pharmaceuticals Incorporated to Report Q4, 2021 Results on Feb 17, 2022 Feb 10
Investor sentiment deteriorated over the past week Jan 15
CEO & Executive Director recently sold €421k worth of stock Nov 13
Third quarter 2021 earnings released: EPS US$0.82 (vs US$0.42 loss in 3Q 2020) Nov 10
Investor sentiment improved over the past week Nov 04
Investor sentiment improved over the past week Sep 01
Second quarter 2021 earnings released: EPS US$1.84 (vs US$1.38 in 2Q 2020) Jul 31
Ligand’s Partner Merck Receives FDA Approval for VAXNEUVANCE™ for the Prevention of Invasive Pneumococcal Disease in Adults Caused by 15 Serotypes Jul 20
Ligand Pharmaceuticals Incorporated(NasdaqGM:LGND) dropped from Russell 2000 Growth-Defensive Index Jun 28
Ligand Pharmaceuticals Incorporated(NasdaqGM:LGND) dropped from Russell 2000 Defensive Index Jun 27
First quarter 2021 earnings released: EPS US$1.10 (vs US$1.46 loss in 1Q 2020) May 05
Ligand Pharmaceuticals Incorporated Provides Earnings Guidance for the Fiscal Year 2021 May 04
Full year 2020 earnings released: US$0.18 loss per share (vs US$33.13 profit in FY 2019) Feb 27
Revenue beats expectations Feb 27
Senior VP recently sold €2.7m worth of stock Feb 06
Revenue beats expectations Feb 05
Ligand Pharmaceuticals Incorporated Updates Financial Guidance for the Year 2021 Feb 04
New 90-day high: €149 Jan 30
Ligand Pharmaceuticals Incorporated to Report Q4, 2020 Results on Feb 03, 2021 Jan 21
New 90-day high: €87.58 Jan 12
Ligand and GSK Enter Global Collaboration and License Agreement Leveraging Icagen's Discovery Technology to Target Neurological Disorders Dec 23
Ligand Pharmaceuticals Incorporated Announces Clinical and Regulatory Progress by Multiple Partners with OmniAb® Antibodies Nov 25
New 90-day low: €67.94 Nov 19
Revenue misses expectations Nov 08
Third quarter 2020 earnings released: US$0.42 loss per share Nov 08
Independent Director recently bought €71k worth of stock Nov 06
Third-quarter earnings released: Revenue misses expectations Oct 30
Third quarter earnings released Oct 30 Shareholder Returns LGDN DE Pharmaceuticals DE Market 7D 0.9% -2.5% -2.6% 1Y 70.3% -15.6% 6.9%
See full shareholder returns
Return vs Market: LGDN exceeded the German Market which returned 6.9% over the past year.
Price Volatility Is LGDN's price volatile compared to industry and market? LGDN volatility LGDN Average Weekly Movement 5.9% Pharmaceuticals Industry Average Movement 5.4% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.2% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: LGDN has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: LGDN's weekly volatility (6%) has been stable over the past year.
About the Company Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19.
Show more Ligand Pharmaceuticals Incorporated Fundamentals Summary How do Ligand Pharmaceuticals's earnings and revenue compare to its market cap? LGDN fundamental statistics Market cap €2.08b Earnings (TTM ) €43.36m Revenue (TTM ) €146.08m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) LGDN income statement (TTM ) Revenue US$152.42m Cost of Revenue US$32.37m Gross Profit US$120.06m Other Expenses US$74.81m Earnings US$45.24m
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/22 23:42 End of Day Share Price 2024/12/20 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Ligand Pharmaceuticals Incorporated is covered by 22 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Jasper Hellweg Argus Research Company Balaji Prasad Barclays Balaji Prasad Barclays
Show 19 more analysts